Aggrastat

Aggrastat

tirofiban

Manufacturer:

Aspen

Distributor:

Zuellig
Concise Prescribing Info
Contents
Tirofiban HCl
Indications/Uses
Used in combination w/ heparin for patients w/ unstable angina or non-Q-wave MI to prevent cardiac ischemic events & for patients w/ coronary ischemic syndromes undergoing coronary angioplasty or atherectomy to prevent cardiac ischemic complications related to abrupt closure of the treated coronary artery.
Dosage/Direction for Use
Dilute Aggrastat prior to administration to achieve a conc of 50 mcg/mL. Unstable angina pectoris or non-Q-wave MI Initial infusion rate: 0.4 mcg/kg/min for 30 min. Maintenance infusion rate: 0.1 mcg/kg/min for 48 hr & up to 108 hr. Angioplasty/atherectomy Initial bolus: 10 mcg/kg administered over 3 min immediately prior to procedure. Maintenance infusion rate: 0.15 mcg/kg/min for 36 hr.
Contraindications
Hypersensitivity. Active internal bleeding; history of intracranial hemorrhage; stroke w/in 30 days; intracranial neoplasm, arteriovenous malformation or aneurysm; malignant HTN; relevant trauma; major surgery w/in past 6 wk; severe liver failure; patients who developed thrombocytopenia following prior exposure to Aggrastat.
Special Precautions
Recent (<1 yr) bleeding, including a history of GI bleeding or genitourinary bleeding of clinical significance; known coagulopathy, platelet disorder or history of thrombocytopenia; platelet count <150,000 cells/mm3; history of cerebrovascular disease w/in 1 yr; recent epidural procedure; cardiopulmonary resuscitation; chronic hemodialysis; puncture of non-compressible vessel w/in 24 hrs; severe acute or chronic heart failure; cardiogenic shock; mild to moderate liver insufficiency; Hb conc <11 g/dL or hematocrit <34%; concurrent administration of non-thienopyridines P2Y12 inhibitors, adenosine, dipyridamole, sulfinpyrazone & prostacyclin arterial access for femoral sheath placement; severe renal insufficiency (CrCl <30 mL/min). Pregnancy, lactation, childn.
Adverse Reactions
Risk of bleeding; nausea; fever; headache.
Drug Interactions
Drugs that affect hemostasis (eg, warfarin).
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AC17 - tirofiban ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Presentation/Packing
Form
Aggrastat infusion conc 250 mcg/mL
Packing/Price
50 mL x 1's (P9,599.45/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in